- Home
- GRDN vs CDNA Comparison
GRDN vs CDNA Comparison
Compare GRDN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRDN
- CDNA
- Stock Information
- Founded
- GRDN 2004
- CDNA 1998
- Country
- GRDN United States
- CDNA United States
- Employees
- GRDN N/A
- CDNA N/A
- Industry
- GRDN Retail-Drug Stores and Proprietary Stores
- CDNA Medical Specialities
- Sector
- GRDN Consumer Staples
- CDNA Health Care
- Exchange
- GRDN Nasdaq
- CDNA Nasdaq
- Market Cap
- GRDN 1.1B
- CDNA 944.1M
- IPO Year
- GRDN 2024
- CDNA 2014
- Fundamental
- Price
- GRDN $20.96
- CDNA $21.17
- Analyst Decision
- GRDN Strong Buy
- CDNA Buy
- Analyst Count
- GRDN 2
- CDNA 8
- Target Price
- GRDN $22.50
- CDNA $27.17
- AVG Volume (30 Days)
- GRDN 141.3K
- CDNA 823.2K
- Earning Date
- GRDN 11-12-2024
- CDNA 11-04-2024
- Dividend Yield
- GRDN N/A
- CDNA N/A
- EPS Growth
- GRDN N/A
- CDNA N/A
- EPS
- GRDN N/A
- CDNA N/A
- Revenue
- GRDN $1,170,907,000.00
- CDNA $312,775,000.00
- Revenue This Year
- GRDN $16.14
- CDNA $19.60
- Revenue Next Year
- GRDN $10.62
- CDNA $10.26
- P/E Ratio
- GRDN N/A
- CDNA N/A
- Revenue Growth
- GRDN 16.86
- CDNA 5.26
- 52 Week Low
- GRDN $14.16
- CDNA $7.42
- 52 Week High
- GRDN $23.05
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- GRDN N/A
- CDNA 31.07
- Support Level
- GRDN N/A
- CDNA $20.77
- Resistance Level
- GRDN N/A
- CDNA $24.42
- Average True Range (ATR)
- GRDN 0.00
- CDNA 1.34
- MACD
- GRDN 0.00
- CDNA 0.05
- Stochastic Oscillator
- GRDN 0.00
- CDNA 9.69
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.